Ikena Oncology Statistics
Total Valuation
Ikena Oncology has a market cap or net worth of $68.53 million. The enterprise value is -$79.08 million.
| Market Cap | 68.53M |
| Enterprise Value | -79.08M |
Important Dates
The last earnings date was Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 33.10% in one year.
| Shares Outstanding | 48.26M |
| Shares Change (YoY) | +33.10% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 95.61% |
| Float | 14.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.81 |
| Forward PS | n/a |
| PB Ratio | 0.44 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.85, with a Debt / Equity ratio of 0.06.
| Current Ratio | 15.85 |
| Quick Ratio | n/a |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.00% and return on invested capital (ROIC) is -47.32%.
| Return on Equity (ROE) | -44.00% |
| Return on Assets (ROA) | -37.30% |
| Return on Capital (ROIC) | -47.32% |
| Revenue Per Employee | $89,488 |
| Profits Per Employee | -$1.63M |
| Employee Count | 43 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -135,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.93% in the last 52 weeks. The beta is 0.34, so Ikena Oncology's price volatility has been lower than the market average.
| Beta (1Y) | 0.34 |
| 52-Week Price Change | -77.93% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 59.30 |
| Average Volume (30 Days) | 360,329 |
Short Selling Information
The latest short interest is 1.52 million, so 3.14% of the outstanding shares have been sold short.
| Short Interest | 1.52M |
| Short Previous Month | 1.39M |
| Short % of Shares Out | 3.14% |
| Short % of Float | 10.78% |
| Short Ratio (days to cover) | 6.83 |
Income Statement
In the last 12 months, Ikena Oncology had revenue of $3.85 million and -$70.09 million in losses. Loss per share was -$1.57.
| Revenue | 3.85M |
| Gross Profit | 3.85M |
| Operating Income | -78.13M |
| Pretax Income | -70.23M |
| Net Income | -70.09M |
| EBITDA | -67.40M |
| EBIT | -70.23M |
| Loss Per Share | -$1.57 |
Balance Sheet
The company has $157.35 million in cash and $9.75 million in debt, giving a net cash position of $147.60 million or $3.06 per share.
| Cash & Cash Equivalents | 157.35M |
| Total Debt | 9.75M |
| Net Cash | 147.60M |
| Net Cash Per Share | $3.06 |
| Equity / Book Value | 155.35M |
| Book Value Per Share | 3.22 |
| Working Capital | 151.00M |
Cash Flow
In the last 12 months, operating cash flow was -$78.26 million and capital expenditures -$202,000, giving a free cash flow of -$78.47 million.
| Operating Cash Flow | -78.26M |
| Capital Expenditures | -202,000 |
| Free Cash Flow | -78.47M |
| FCF Per Share | -$1.63 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,030.33% and -1,821.54%.
| Gross Margin | 100.00% |
| Operating Margin | -2,030.33% |
| Pretax Margin | -1,825.05% |
| Profit Margin | -1,821.54% |
| EBITDA Margin | -1,751.51% |
| EBIT Margin | -1,825.05% |
| FCF Margin | -2,039.11% |
Dividends & Yields
Ikena Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.10% |
| Shareholder Yield | -33.10% |
| Earnings Yield | -102.29% |
| FCF Yield | -114.50% |
Analyst Forecast
The average price target for Ikena Oncology is $10.67, which is 646.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.67 |
| Price Target Difference | 646.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 54.12% |
| EPS Growth Forecast (5Y) | -13.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ikena Oncology has an Altman Z-Score of -0.33 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.33 |
| Piotroski F-Score | 1 |